Fennec's elite Rule of 40 score, positive free cash flow, and bullish technical breakout are counterbalanced by concentration in a single product and manufacturer plus recent insider selling, leaving the stock a hold rather than a clear add.
Thesis pillars
- Elite Rule Of 40 With Gaap Loss→Stable
- Single Product Concentration Risk↓Deteriorating
- Bullish Breakout Technical Setup→Stable
- +2 more pillars — see the Why tab for full reasoning
Fennec Pharmaceuticals Inc. (FENC) Stock Analysis
Inst Constrain edge
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $10.35, but acceptable to hold if already in. Reasons: Concentration risk — Product: PEDMARK; Concentration risk — Supplier: third-party contract manufacturer (PEDMARK).
Fennec Pharmaceuticals is a commercial-stage specialty pharmaceutical company with a single approved product, PEDMARK (sodium thiosulfate injection), the only FDA- and EU-approved therapy to reduce the risk of cisplatin-induced hearing loss in pediatric cancer patients. The... Read more
Hold if already holding. Not a fresh buy at $10.35, but acceptable to hold if already in. Reasons: Concentration risk — Product: PEDMARK; Concentration risk — Supplier: third-party contract manufacturer (PEDMARK). Chart setup: No clear chart pattern; technical signals are mixed. Market cap $363M below $400M minimum. Not in investable universe. Score 6.5/10, moderate confidence.
Passes 6/8 gates (favorable risk/reward ratio, no SEC red flags, news events none recent, earnings proximity 35d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and clean insider activity. Suitability: speculative.
About Fennec Pharmaceuticals Inc.
About Fennec Pharmaceuticals Inc.
PEDMARK (sodium thiosulfate injection) is Fennec Pharmaceuticals' only approved product and the sole FDA- and EU-approved therapy to reduce cisplatin-induced ototoxicity in pediatric cancer patients, commercially available in the U.S. since October 2022. Fennec licensed PEDMARQSI, the European brand, to Norgine in March 2024 for Europe, Australia, and New Zealand in exchange for $43 million upfront and up to $230 million in additional milestones plus royalties up to the mid-twenties percent, though no milestone payments have been received to date. The company held $36.8 million in cash as of December 31, 2025 and holds orphan drug exclusivity for PEDMARK through September 2029.
Fennec earns revenue from U.S. sales of PEDMARK, distributed through a small group of exclusive specialty pharmacies, and from its Norgine partnership, which pays milestone and royalty income for European commercialization while Norgine bears all commercialization costs and holds the marketing authorizations in its licensed territories. In 2025 the company also signed a distribution agreement with Inpharmus for Turkey and the Gulf Cooperation Council, under which Fennec supplies product and receives payments while Inpharmus handles regulatory and commercialization work, and it is pursuing a similar partnering strategy in Japan following positive results from an investigator-initiated trial there. PEDMARK is manufactured entirely by third-party contract manufacturers rather than in-house, and the company has previously received two FDA complete response letters, in August 2020 and November 2021, tied to deficiencies at its third-party manufacturing facility. Fennec settled patent litigation with Cipla in March 2026, under which Cipla agreed not to launch a generic sodium thiosulfate product before September 1, 2033.
Show full overview
Fennec's manufacturing is entirely outsourced, and the 10-K cites a concrete, dated example of how that dependency has bitten before: the FDA issued complete response letters in August 2020 and November 2021 specifically because of deficiencies at the third-party facility that manufactures PEDMARK on its behalf, delaying the product's eventual September 2022 approval. The company says it intends to maintain a second manufacturing source where feasible, but acknowledges that establishing a replacement contract manufacturer is difficult given the lead times required to manufacture drugs and the need for FDA compliance inspections. Because PEDMARK is Fennec's only product and substantially all of its near-term revenue, any repeat of a CRL-triggering manufacturing deficiency would fall on a single, already-thin revenue base rather than being absorbed across a diversified product portfolio.
See also: Healthcare · Biotechnology
From Fennec Pharmaceuticals Inc.'s most recent 10-K filing, extracted August 23, 2026.
Recent developments
updated 2026-10-07Recent Developments — Fennec Pharmaceuticals Inc.
Latest news
Generated 2026-10-07T11:32:04Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductPEDMARK10-K Item 1A: 'we expect that all of our product revenues in the foreseeable future will be from sales of PEDMARK®'
- HIGHSupplierthird-party contract manufacturer (PEDMARK)10-K Item 1A: 'deficiencies in the third-party manufacturing facility that manufactures PEDMARK® on our behalf is a specific example of the risks associated with our third-party manufacturers'
- HIGHSupplierexclusive specialty pharmacies10-K Item 1A: 'we are using a very small group of exclusive specialty pharmacies to distribute our product'
- MEDIUMcounterpartyNorgine10-K Item 1A: 'Our international commercialization strategy depends on collaborative relationships with our third party development partners, including Norgine in Europe'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $10.35, but acceptable to hold if already in. Reasons: Concentration risk — Product: PEDMARK; Concentration risk — Supplier: third-party contract manufacturer (PEDMARK). Chart setup: No clear chart pattern; technical signals are mixed. Market cap $363M below $400M minimum. Not in investable universe. Target $15.37 (+48.5%), stop $9.71 (−6.6%), A.R:R 5.1:1. Score 6.5/10, moderate confidence.
Take-profit target: $15.37 (+48.5% upside). Target $15.37 (+48.5%), stop $9.71 (−6.6%), A.R:R 5.1:1. Stop-loss: $9.71.
Concentration risk — Product: PEDMARK; Concentration risk — Supplier: third-party contract manufacturer (PEDMARK); Market cap $363M below $400M minimum.
Fennec Pharmaceuticals Inc. trades at a P/E of N/A (forward 10.9). TrendMatrix value score: 8.1/10. Verdict: Hold.
12 analysts cover FENC with a consensus score of 4.2/5. Average price target: $18.
What does Fennec Pharmaceuticals Inc. do?Fennec Pharmaceuticals is a commercial-stage specialty pharmaceutical company with a single approved product, PEDMARK...
Fennec Pharmaceuticals is a commercial-stage specialty pharmaceutical company with a single approved product, PEDMARK (sodium thiosulfate injection), the only FDA- and EU-approved therapy to reduce the risk of cisplatin-induced hearing loss in pediatric cancer patients. The company sells PEDMARK directly in the United States and licenses PEDMARQSI, the European brand name, to Norgine for Europe, Australia, and New Zealand under a deal that has already paid $43 million upfront with up to $230 million in additional milestones and royalties up to the mid-twenties percent. Fennec held $36.8 millio